2-(3-溴苯基)丙二腈 | 297745-45-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3-溴苯基)丙二腈
• 英文名称: 2-(3-Bromophenyl)malononitrile
• 英文别名: 3-Bromophenylmalononitrile；2-(3-bromophenyl)propanedinitrile
• CAS: 297745-45-0
• 化学式: C₉H₅BrN₂
• 分子量: 221.056
• InChiKey: VARPTKFFDRCPMG-UHFFFAOYSA-N

物化性质

• 熔点：
  99-101 °C
• 沸点：
  324.7±27.0 °C(Predicted)
• 密度：
  1.551±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  47.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-溴苯基)丙二腈 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 (Z)-3-amino-3-(2-aminophenyl)sulfanyl-2-[3-[furan-3-yl(hydroxy)methyl]phenyl]prop-2-enenitrile
  参考文献：
  名称：

  Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors

  摘要：

  Employing phenylmalonitrile dianion chemistry, a large number of analogues of MEK inhibitor lead SH053 (IC50 = 140 nM) were rapidly synthesized leading to single digit nM inhibitors, displaying submicromolar AP-1 transcription inhibition in COS-7 cells. Compound 41, exhibiting a MEK IC50 = 12 nM showed ip activity in a TPA-induced car edema model with an ED50 = 5 mg/kg. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.012
• 作为产物：
  描述：

  硫氰酸2-氯苯甲酯 、 3-溴氰苄 在 正丁基锂 、 二异丙胺 、 lithium diisopropyl amide 作用下， 以 苯 为溶剂， 反应 1.0h， 以79.9%的产率得到2-(3-溴苯基)丙二腈
  参考文献：
  名称：

  Amino-thio-acrylonitriles as MEK inhibitors

  摘要：

  这项发明通常涉及式Ia或Ib的氨基硫基丙烯腈：作为MEK抑制剂，含有该化合物的药物组合物，以及使用该化合物用于治疗和预防炎症性疾病或作为抗癌放射增敏剂的方法。

  公开号：

  US06703420B1

文献信息

• 7,7-Dicyano-8,8-bis[4-(<i>N</i>,<i>N</i>-dimethylamino)phenyl]-<i>meta</i>-xylylenes: The First Stable Zwitterionic Metaxylylene Derivatives
  作者：Takeshi Kawase、Tohru Iwata、Masaji Oda

  DOI：10.1246/cl.2003.322

  日期：2003.4

  Treatment of 3-lithiophenyldicyanomethide ions with Michler’s ketone afforded the title compounds as stable crystals upon weak-acidic work-up. The molecular structure and spectroscopic data reveal the zwitterionic nature of the compounds.

  用米迦勒酮处理3-锂苯基二氰甲烷离子，在弱酸性条件下得到稳定的标题化合物晶体。分子结构和光谱数据显示这些化合物具有两性离子性质。
• Methods for treating seizure disorders by inhibiting MAPK pathway activation
  申请人：——

  公开号：US20020058699A1

  公开（公告）日：2002-05-16

  Excessive brain neuronal excitability, associated with a seizure disorder, can be correlated with increased mitogen-activated protein kinase (MAPK) activity in neurons. Such excessive excitability can be ameliorated by administering an effective amount of a compound, such as a MAPK phosphorylation or kinase activity inhibitor, that reduces the amount of MAPK activity in neurons of an individual suffering from a seizure disorder. Compounds that inhibit phosphorylation or kinase activity of upstream activators or downstream targets of the MAPK cascade also are useful in this context.

  过度的脑神经兴奋，与癫痫病有关，可能与神经元中丝裂原活化蛋白激酶（MAPK）的活性增加相关。通过给患有癫痫病的个体施用有效量的化合物，如MAPK磷酸化或激酶活性抑制剂，可以减少神经元中MAPK活性的数量，从而改善这种过度的兴奋。抑制MAPK级联的上游激活剂或下游靶标的磷酸化或激酶活性的化合物在这种情况下也是有用的。
• [EN] AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS<br/>[FR] AMINO-THIO-ACRYLONITRILES UTILISES COMME INHIBITEURS DES KINASES MEK
  申请人：DU PONT PHARM CO

  公开号：WO2000056706A1

  公开（公告）日：2000-09-28

  This invention relates generally to amino-thio-acrylonitriles of formula (Ia) or (Ib) as MEK inhibitors, pharmaceutical compositions containing the same, and methods of using the same as for treatment and prevention of inflammatory disorders or as an anticancer radiosensitizing agent.

  本发明涉及一般式(Ia)或(Ib)的氨基硫基丙烯腈作为MEK抑制剂，含有相同的药物组合物，以及将其用于治疗和预防炎症性疾病或作为抗癌放射增敏剂的方法。
• 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications
  申请人：GRELAN PHARMACEUTICAL CO., LTD.

  公开号：EP0714893A1

  公开（公告）日：1996-06-05

  Unique benzothiazole derivatives which exert superior aldose redactase inhibiting actions are unexpectedly and advantageously useful in the prophylactic and therapeutic treatment of diabetic complications. A benzothiazole derivative compound of the formula (1): wherein X is halogen, R¹ and R², which are the same or different, are each independently hydrogen or halogen, A is a methylene group or a sulfur atom, and -B-COOR³ is a group selected from the group consisting of (2) to (5): wherein R³ is hydrogen or C1 to C3 lower alkyl, Y is hydrogen, halogen, C1 to C3 lower alkyl, carboxyl or dilower alkylamino and n is an integer of 1 to 3; Z is oxygen or sulfur, R⁴ is C1 to C3 lower alkyl, optionally substituted phenyl, optionally substituted benzyl or optionally substituted phenethyl and m is an integer of 2 to 5; or a pharmaceutically acceptable salt and a pharmaceutical composition comprising the same which is a useful prophylactic or therapeutic agent for the treatment of diabetic complications.

  独特的苯并噻唑衍生物具有优异的醛糖还原酶抑制作用，在预防和治疗糖尿病并发症方面具有意想不到的优势。一种式（1）的苯并噻唑衍生物化合物： 其中 X 是卤素，R¹ 和 R²（相同或不同）各自独立地为氢或卤素，A 是亚甲基或硫原子，以及 -B-COOR³ 是选自 (2) 至 (5) 所组成的基团： 其中 R³ 是氢或 C1 至 C3 低级烷基，Y 是氢、卤素、C1 至 C3 低级烷基、羧基或稀释烷基氨基，n 是 1 至 3 的整数；Z 是氧或硫，R⁴ 是 C1 至 C3 低级烷基、任选取代的苯基、任选取代的苄基或任选取代的苯乙基，m 是 2 至 5 的整数；或一种药学上可接受的盐和由其组成的药物组合物，该药物组合物是治疗糖尿病并发症的有效预防或治疗剂。
• AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS
  申请人：Du Pont Pharmaceuticals Company

  公开号：EP1163215A1

  公开（公告）日：2001-12-19